Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as quetiapine fumarate or valproate
quetiapine or valproate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| quetiapine fumarate or valproate | DRUG | - |
Inclusion Criteria: * Signed informed consent, men and women aged ³18 to £65 years with diagnosis of DSM-IV criteria for bipolar I or II disorder, most recent episode manic, hypomanic, mixed or depressive with Rapid Cycling. Exclusion Criteria: * Substance or alcohol dependence, female patients w...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Quetiapine and valproate are studied for the treatment of bipolar disorder, including patients with rapid cycling. A Phase 3 trial compared the two agents in this population. Both are small molecule therapies, and the studied indication is bipolar disorder within the psychiatry therapeutic area.
Quetiapine targets the serotonin receptor HTR2A and the dopamine receptor DRD2, and also HTR2C. These targets are classified as antagonist activity. Valproate is included in the same development program for bipolar disorder, though its molecular target is not the same as quetiapine's receptor profile.
AstraZeneca PLC, which trades under the ticker AZN, is the developer associated with this quetiapine and valproate program in bipolar disorder. The company sponsored the Phase 3 study evaluating quetiapine compared with valproate in patients with bipolar disorder and rapid cycling.
Quetiapine and valproate are in Phase 3 development for bipolar disorder. The program includes one completed Phase 3 trial, and no trials are currently active. The agents are investigational in this development context and are not described here as approved for the studied indication.
The program includes one completed Phase 3 trial, NCT00254774, titled Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling. It enrolled 44 participants in Germany, ages 18 years and older, and was randomized but not double blind.
No. Quetiapine, also known as quetiapine fumarate, and valproate are two distinct agents that were compared against each other in a Phase 3 bipolar disorder trial. Quetiapine is a small molecule targeting HTR2A, DRD2 and HTR2C, while valproate is a separate compound studied in the same program.